Targeting Sepiapterin Reductase to Treat Neuropathic Pain

Alban Latremoliere, Michael Costigan, and Clifford Woolf describe how they genetically manipulated the tetrahydrobiopterin synthesis pathway in mice to formally validate its role in neuropathic and inflammatory pain hypersensitivity and show that inhibition of this pathway by targeting sepiapterin reductase both reduces chronic pain without adverse effects and generates a treatment biomarker.